Algeta ASA : Further sub-analyses of ALSYMPCA phase III study presented at 2013 Genitourinary Cancers Symposium

Not Intended for US Media Abstracts #11 & #19 Effects of radium-223 dichloride on skeletal-related events and pain associated with bone metastases from castration-resistant prostate cancer Oslo, Norway, 15 February 2013 - Algeta ASA (OSE: ALGETA) announces that further analyses of data subsets from the phase III ALSYMPCA study of radium-223 dichloride (radium-223) in castration-resistant prostate cancer (CRPC) patients have been presented at the 2013 Genitourinary Cancers Symposium[1] (14-16 February 2013, Orlando, FL, USA). Gillies O'Bryan-Tear, Algeta's Chief Medical Officer, said: "These additional analyses from ALSYMPCA demonstrate that, in addition to prolonging survival in CRPC patients with bone metastases, radium-223 also improves clinically relevant endpoints related to complications from bone metastases. If approved, radium- 223 has the potential to play a key role in the treatment of men with CRPC that has metastasized to the bone." Abstract #11 by Vogelzang et al. found that radium-223 treatment significantly delayed time to first skeletal-related event (SRE) versus placebo by a median increase of 5.8 months (median time to SRE: 15.6 vs 9.8 months; HR=0.658; P<0.001). The analysis also showed that, compared to placebo in CRPC patients with bone metastases, treatment with radium-223 reduced the risk of time to first event for all four SRE components, including a 48% reduction in risk for spinal cord compression. Abstract #19 by Nilsson et al. described an analysis of pain parameters in ALSYMPCA. The analysis showed that, compared to placebo in CRPC patients with bone metastases, patients treated with radium-223 had significantly prolonged median time to first palliative external beam radiotherapy (EBRT) (HR=0.670, P=0.00117) and in a post-hoc analysis patients treated with radium-223 had significantly prolonged median time to initial opioid use, with a risk reduction of 38% compared to placebo (HR=0.621). In the ALSYMPCA trial the most common hematologic adverse events for patients treated with radium-223 and best standard of care (BSoC) and compared to placebo and BSoC included anemia (31% vs. 31%), neutropenia (5% vs. 1%) and thrombocytopenia (12% vs. 6%). With respect to Grade 3 and 4 adverse events, the most common events included anemia (13% vs. 13%), neutropenia (2% vs. 1%) and thrombocytopenia (6% vs. 2%). The most common non-hematologic adverse events in patients treated with radium-223 and BSoC compared to placebo and BSoC included bone pain (50% vs. 62%), nausea (36% vs. 35%), diarrhea (25% vs. 15%) and vomiting (19% vs. 14%). With respect to Grade 3 to 4 adverse events, the most common events included bone pain (21% vs. 26%). References Abstract #11 - Vogelzang, N. et al. Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration- resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA). Abstract #19 - Nilsson, S. et al. Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases. ### About the ALSYMPCA Trial The ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial was a phase III, randomized, double-blind, placebo-controlled international study of radium-223 with best standard of care (BSoC) vs placebo with BSoC in symptomatic CRPC patients with bone metastases. The trial enrolled 921 patients in more than 100 centers in 19 countries. The study treatment consisted of up to six intravenous administrations of radium-223 or placebo each separated by an interval of four weeks. The primary endpoint of the study was overall survival. Secondary endpoints included time to occurrence of skeletal-related events (SRE), time to total alkaline phosphatase (ALP) and prostate-specific antigen (PSA) progression, total ALP response and normalization, safety, and quality of life. About CRPC and Bone Metastases Prostate cancer is the most common non-cutaneous malignancy in men worldwide. In 2008, an estimated 899,000 men were diagnosed with prostate cancer and 258,000 died from the disease worldwide. Prostate cancer is the sixth leading cause of death from cancer in men. A majority of men with CRPC have radiological evidence of bone metastases. Once the cancer cells settle in the bone, they interfere with bone strength, often leading to pain, fracture and other complications that can significantly impair a man's health. Bone metastases secondary to prostate cancer typically target the lumbar spine, vertebrae and pelvis. In fact, bone metastases are the main cause of morbidity and death in patients with CRPC. About Radium-223 Dichloride Radium-223 dichloride (radium-223), formerly referred to as Alpharadin, is a therapeutic alpha particle-emitting pharmaceutical with targeted anti-tumor effect on bone metastases in development for CRPC patients with bone metastases. In September 2009, Algeta signed an agreement with Bayer Pharma AG (Berlin, Germany) for the development and commercialization of radium-223. Under the terms of the agreement, Bayer will develop, apply for global health authority approvals, and commercialize radium-223 globally. Algeta will co-promote radium- 223 with Bayer in the US, and is eligible for milestones as well as royalties on Bayer's sales outside the US. The ALSYMPCA trial was initiated by Algeta in June 2008. Radium-223 is an investigational agent and is not approved by the European Medicines Agency (EMA), the US Food and Drug Administration (FDA) or other health authorities. Bayer submitted a Marketing Authorization Application to the EMA and a New Drug Application to the FDA for radium-223 in December 2012 for the treatment of CRPC patients with bone metastases, and received priority review for the NDA in the US. In terms of further development activities for radium-223, Bayer intends to conduct studies in earlier settings of prostate cancer, including combination studies with other agents, as well as exploratory studies in other tumors such as breast cancer and osteosarcoma. For further information, please contact: Mike Booth +47 2202 4510 Communications & Corporate Affairs ir@algeta.com Media enquiries: Mark Swallow +44 207 638 9571 Citigate Dewe Rogerson mark.swallow@citigatedr.co.uk Knut Ekern +47 22 04 82 00 Gambit Hill & Knowlton knut.ekern@hkstrategies.com US investor enquiries: Tricia Swanson +1 646 378 2953 The Trout Group tswanson@troutgroup.com About Algeta Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com. Forward-looking Statements This news release contains certain forward-looking statements that are based on uncertainty, as they relate to events and depend on circumstances that will occur in the future and which, by their nature, may have an impact on results of operations and the financial condition of Algeta. Such forward-looking statements reflect our current views and are based on the information currently available to Algeta. Algeta cannot give any assurance as to whether such forward looking statements will prove to be correct. These forward looking statements include statements regarding our anticipated co-promotion of radium-223 in the US.  There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. These factors include, among other things, risks or uncertainties associated with the ability to identify and hire a sufficient number of qualified employees for the US field force, growth management, general economic and business conditions and the pricing environment, the impact of competition, the ability to successfully commercialize radium-223, the risk that costs associated with the co-promotion of radium-223 may be greater than anticipated, manufacturing capacity, the risk of non-approval of patents not yet granted, risks in obtaining regulatory approvals for radium-223 and the other risks and uncertainties described in our annual report. [1]The 2013 Genitourinary Cancers Symposium is co-sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO). This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Press release: http://hugin.info/134655/R/1678363/547752.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Algeta ASA via Thomson Reuters ONE [HUG#1678363]